Evidence map›Paper›PMID 29603092›Full record

ArticleMolecular neurobiology2018

MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease.

Paul M McKeever, Raphael Schneider, Foad Taghdiri, Anna Weichert, Namita Multani, Robert A Brown, Adam L Boxer, Anna Karydas, Bruce Miller, Janice Robertson and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 9 pooled it
5.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 9 syntheses or guidelines pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The characteristic expression of circulatingFrontiers in endocrinology · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Extracellular Vesicles in Tauopathies: Mechanisms and Applications.International journal of molecular sciences · 2026
    Review
  17. Article
  18. Review
  19. Review
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Paul M McKeeverTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada.
Raphael SchneiderTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada.
Foad TaghdiriTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada.
Anna WeichertTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada.
Namita MultaniTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada.
Robert A BrownMontreal Neurological Institute, McGill University, Montreal, QC, Canada.
Adam L BoxerMemory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Anna KarydasMemory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Bruce MillerMemory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Janice RobertsonTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, 60 Leonard Ave., 4KD-481, Toronto, ON, M5T 2S8, Canada. carmela.tartaglia@uhn.ca.
University of Toronto · CAUniversity of California, San Francisco · USMontreal Neurological Institute and Hospital · CAUniversity Health Network · CAUniversity Memory and Aging Center · US

Funding

PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, YADONG · 2004 to 2018
$27.1M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG038791NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

Clinical diagnosis of Alzheimer's disease (AD) prior to the age of 65 years is classified as young-onset (YOAD), whereas diagnosis after the age of 65 years is considered late-onset (LOAD). Although rare autosomal mutations more commonly associate with YOAD, most YOAD and LOAD cases are sporadic. YOAD and LOAD share amyloid and tau pathology, but many YOAD patients show increased disease severity and rate of progression. The current study examined the microRNA (miRNA) expression profile from exosomes isolated from the cerebrospinal fluid (CSF) of YOAD patients with biomarker-confirmed AD. Results uncovered miR-16-5p, miR-125b-5p, miR-451a, and miR-605-5p as differentially expressed in the CSF-derived exosomes of YOAD patients when compared with healthy controls (HC). In a cohort of LOAD patients, miR-125b-5p, miR-451a, and miR-605-5p were similarly altered in expression, but miR-16-5p showed similar expression to control. Analysis of the mRNA targets of these miRNAs revealed transcripts enriched in biological processes relevant to the post-mortem posterior cingulate cortex transcriptome in YOAD from a previously published microarray study, including those related to neuron projections, synaptic signaling, metabolism, apoptosis, and the immune system. Hence, these miRNAs represent novel targets for uncovering disease mechanisms and for biomarker development in both YOAD and LOAD.

Indexed as

AgedAge of OnsetAlzheimer DiseaseCase-Control StudiesExosomesFemaleGene Expression ProfilingGene OntologyGyrus CinguliHumansMaleMicroRNAsMiddle AgedReproducibility of ResultsMicroRNAsAlzheimer’s diseaseCerebrospinal fluidExosomesMicroRNAYoung-onset

Identifiers

PMID29603092
PMCPMC6208843
OpenAlexW2795207192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.